Live Terminal

Sun Pharma board approves plan to raise up to ₹10,000 crore via NCDs

Share on WhatsApp Telegram
⚡ Instant Key Takeaways (TL;DR)
🎯
Core Development: Sun Pharma board approves plan to raise up to ₹10,000 crore via NCDs
📊
Market & Financial Impact: The decision was taken at a meeting of the company's Board of Directors held on October 12, Sun Pharma said in a regulatory filing
💡
Actionable Insight: Monitor price volume action at market open; check key technical support/resistance levels.

Sun Pharmaceutical Industries has said its board of directors has approved a proposal to raise funds of up to Rs 10,000 crore.

Sun Pharmaceutical Industries has said its board of directors has approved a proposal to raise funds of up to Rs 10,000 crore through the issuance of non-convertible debentures (NCDs).

The decision was taken at a meeting of the company's Board of Directors held on October 12, Sun Pharma said in a regulatory filing late on Monday evening.

The board approved the issuance of listed, rated, unsecured, redeemable NCDs on a private placement basis in one or more tranches and/or series for an aggregate amount not exceeding Rs 10,000 crore.

The company said that disclosures required under Regulation 30 of the Sebi (Listing Obligations and Disclosure Requirements) Regulations, 2015, will be made at an appropriate stage upon the issuance or allotment of the debentures.

📰
Official Publisher Attribution: This report is aggregated from Business Standard. ZeroLive provides live aggregation, automated sentiment synthesis, and exchange disclosure monitoring for retail market participants.
Read Original Full Coverage on Business Standard ↗
Link copied to clipboard! ✅